1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Company is focused on two business segments:

1) Industrial Hemp: This division is focused on, but not limited to, the carbon negative use of hemp-based construction materials and carbon neutral bio-energy sources.

2) Biopharma: The Health and Wellness Division is acquiring exclusive licensing of patents and other IP. To date the Company has executed agreements for partnerships with companies like B-Organic R&D Corp. and Apollon Formularies plc.

The Company continues to work on expanding both these segments with additional opportunities and people to assist in developing its business segments.

On October 11, 2023 GHG announced the execution of a Letter of Intent with B-Organic R&D Corp. to exclusively license its Bioactive Lipid Agents (“BLA”) technology, a patented innovative matrix which is able to increase the solubility and bioavailability of numerous “poorly soluble pharma ingredients” including cannabinoids. The application of BLA extends to numerous industries such as food, pharmaceuticals, healthcare, drugs, agriculture, and nutraceuticals.

This LOI marks the next step in the Company’s strategic expansion of its bio pharma business segment. Earlier this year, GHG successfully launched this segment with the Exclusive Licensing of Apollon Formularies plc patents and intellectual property. Research is also an important component of this expanding business segment. The Company will work with the B-Organic team in collaboration with Prof. Víctor M. Castaño, Ph.D., head of GHG’s R&D team, to bring together additional advisors that can assist in developing this business segment.

Background on Bioactive Lipid Agents (“BLA”)

Through many years of research, B-Organic has developed and patented an innovative matrix, which will change Pharmaceutical, nutraceutical and well as the hemp/cannabis industry. B-Organic’s Innovative Matrix has demonstrated to be able
to increase the solubility and bioavailability of numerous “poorly soluble pharma ingredients” including cannabinoids.

The technology has been patented as Bioactive Lipid Agents Under Water Dispersible Solid Forms for Food, Nutraceutical, Agricultural and Pharmaceutical - Patent Number: PCT/CA2015/00017. Because of their ongoing work utilizing BLA on medical cannabis, B-Organic also possesses a Cannabis Research License issued by Health Canada.

With B-Organic’s patented technology, research has demonstrated that the following can be achieved with cannabinoids:

- Conversion of cannabinoids into solid powders permitting to broaden the application field under different dosage forms: tablets, capsules, patch for pharmaceutical application or for recreational use as powders (ready to use) in sugar sachet form, easily added to food, drinks, energy drinks, baking goods, dairy products, etc.
- 100 % Generally Recognized As Safe (“GRAS”)
- Excipient FDA Cleared
- Increase the bioavailability of the cannabinoids (and its analogues): less active ingredient is required in order to target the same dosage or effect, thus resulting in a decrease in cost and improve the safety
- Accurate dosing for immediate or controlled release of the cannabinoids or its derivatives
- Reduced side effects
- Conversion process requires no chemicals, no solvents, and no heat
- Cannabinoid odor can be reduced if desired
- Costs are low and product is simple to manufacture

Non-Brokered Private Placement Pursuant to Listed Issuer Financing (LIFE) Exemption

On October 16, 2023 the Company announced its intention to complete a non-brokered private placement of up to 8,970,740 common shares of the Company (the “Common Shares”) at a price of $0.05 per Common Share for gross proceeds of up to $448,537 (the "Offering"). Proceeds from the sale of the Offering are intended for general working capital purposes.

At the closing of the Offering, the Company may (i) pay to certain finders a cash commission up to 8.0% of the gross proceeds of the Offering resulting from subscribers introduced by such finders, and (ii) issue to such finders Common Share purchase warrants (the “Finder Warrants”), exercisable for a period of two (2) years at an exercise price of $0.05 following the closing of the Offering, to acquire in aggregate that number of Common Shares which is up to 8.0% of the number of Common Shares sold under the Offering attributable to the finders.
The Offering is scheduled to close in one or more tranches with the final closing no later than November 29, 2023, and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the Canadian Securities Exchange.

Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions (“NI 45-106”), the Common Shares will be offered for sale to purchasers in Canada pursuant to the listed issuer financing exemption under Part 5A of NI 45-106 (the “Listed Issuer Financing Exemption”). Because the Offering is being completed pursuant to the Listed Issuer Financing Exemption, the securities issued in the Offering will not be subject to a hold period pursuant to applicable Canadian securities laws.

There is an offering document related to this Offering that can be accessed under the Company’s profile at [www.sedarplus.com](http://www.sedarplus.com) and on the Company’s website at [https://www.globalhempgroup.com/investor-information](https://www.globalhempgroup.com/investor-information). Prospective investors should read this offering document before making an investment decision.

2. Provide a general overview and discussion of the activities of management.  
   See #1 above.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.  
   NONE

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.  
   None

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.  
   On October 11, 2023 GHG announced the execution of a Letter of Intent (“LOI”) with B-Organic R&D Corp. (“B-Organic”) to exclusively license its Bioactive Lipid Agents (“BLA”) technology, a patented innovative matrix which is able to increase the solubility and bioavailability of numerous “poorly soluble pharma ingredients” including cannabinoids. The application of BLA extends to numerous industries such as food, pharmaceuticals, healthcare, drugs, agriculture, and nutraceuticals.

   **Deal Terms**

   Exclusive Licensing - B-Organic, a bio-chemical research company that concentrates on the development of molecular structures that have scientific or commercial value for industry partners in the Pharmaceutical, Nutraceutical and Agricultural sectors is exclusively licensing the application of its Bioactive Lipid Agents technology for development/enhancement of products which include any form of cannabinoid,
including terpenes or flavonoids, as well as compounds extracted from functional mushrooms, either alone or in any combination (the “Application”).

The Parties will look to work together by way of establishing a collaboration and/or joint venture (“JV”) through a new entity to be formed by way of a share allocation on a 50/50 basis (the “Proposed Transaction”).

Definitive Agreement - The Parties will now move forward on completing a definitive agreement (the “Definitive Agreement”) setting forth the detailed terms of the Proposed Transaction which shall contain, but not limited to, milestones, budgets, terms and conditions as set out in the LOI, and such other terms and conditions as are customary for transactions of the nature and magnitude contemplated herein. All Proposed Transaction documents shall be in form and content satisfactory to GHG and B-Organic and their respective boards of directors and counsel. GHG has been granted an exclusive period to November 30, 2023 to complete the Definitive Agreement, unless mutually extended in writing by the Parties.

Reimbursement of Investment - All initial revenues generated from any products developed by the JV will be used to reimburse GHG for its cumulative investment, before distribution of any remaining proceeds as defined in the Proposed Transaction documents. In the case of a mutual agreement by the founding JV partners to sell the JV company or to expand the ownership of the JV to third parties, GHG will have its cumulative investment repaid from proceeds prior to any allocations. Such reimbursement is not applicable in case of the termination of this Letter of Intent.

Termination of the Letter of Intent - This LOI may be terminated by: a) mutual written consent by both Parties; b) if the Parties have not entered or failed to agree and sign, at their sole discretion, the requisite Definitive Agreement on or before November 30, 2023; c) if the research funding is not reached, prior to signing the Definitive Agreement, unless mutually extended and signed by both Parties.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None

7. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None

8. Describe the acquisition of new customers or loss of customers.

None

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None
10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.  None

11. Report on any labour disputes and resolutions of those disputes if applicable.  None

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.  None

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.  None

14. Provide details of any securities issued/returned to treasury, and options or warrants granted.

<table>
<thead>
<tr>
<th>Security</th>
<th>Number Issued</th>
<th>Details of Issuance</th>
<th>Use of Proceeds (1)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.  None

16. Provide details of any changes in directors, officers or committee members.

Appointment of Ramsey Douglas as Director

On October 3, 2023 GHG announced that Ramsey Douglas has been appointed Director of the Company.

Ramsey Douglas is a UK professional based in London, whose passion lies in conquering the dynamic challenges of the business world and firmly believes that success in business is a collective effort, driven by the strength of the team.

Since 2017, he became involved in the CBD industry when it was in its infancy in the United Kingdom. Recognizing the need for stability and quality, Mr. Douglas, as Managing Director, spearheaded the World CBD Awards, with the clear mission; identify the world’s finest CBD brands through rigorous scientific evaluation and full traceability to the source. This enabled him to partner with some of the world’s leading brands, developing a global contact base, together with establishing relationships with some of the leading media agencies globally with the objective to get clearly defined messages out to mass markets.

Concurrently, Mr. Douglas helmed United Hemp Alliance, a global CBD distribution company, that sold raw materials right through to finished products. In addition, he has been following the medicinal cannabis space for the last several years to understand the global landscapes, legalities, growth potentials and potential gaps in the market. Having been in the CBD space for the last 6 years, medicinal cannabis was
the next generation, and an industry that his group had aspirations of entering and had been building in the background.

In late 2022, he set his sights on the growing medicinal cannabis sector and looked at innovative ways in which his group could enter the space, and how they could help people with non-addictive alternative medications, without the stigmas being attached. They then set about understanding the biggest disconnect across the medicinal cannabis space, being education, and put a plan in place on how they could address this on a global level.

With industry pioneers entering the fray, Ramsey saw a wealth of opportunities at the industry’s dawn, fueled by the strong global relationships that had been cultivated, the solid team and advisory board that they built, and lessons learned from the CBD sector, they created a company CannoV8, a company to take advantage of this opportunity.

Prior to his entrance into the CBD industry, Mr. Douglas’ professional journey began in the corporate realm, where he navigated the intricacies of global IT manufacturing, across Europe, the Middle East, and Africa (EMEA). During that time, he led diverse sales channels, overseeing delivery, and shaping marketing and sales strategies, with the overall objective being to outwit the competition across the focus market areas.

Appointment of Veronique Laberge as CFO

On October 16, 2023 the Company announced that Véronique Laberge, CPA Auditor, an existing Director of the Company had been appointed the Company’s Chief Financial Officer, replacing Rachel Lu, the Company’s current CFO.

Véronique Laberge began her career in an accounting firm in 2005. She participated in various certification mandates for private companies. Mrs. Laberge then chose to pursue her career in a management position in the field of professional services, an experience that allows her to acquire solid expertise in the business world. In 2018, Mrs. Laberge returned to professional practice as a self-employed practitioner. With more than 17 years of experience in professional practice, she now specialized as a consultant and fractional CFO for public and private companies.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

None

Certificate of Compliance

The undersigned hereby certifies that:
1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there where is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **November 5, 2023**.

**Curt Huber**
Name of Director or Senior Officer

**“Curt Huber”**
Signature

**Director**
Official Capacity

<table>
<thead>
<tr>
<th><strong>Issuer Details</strong></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name of Issuer</strong></td>
<td></td>
<td><strong>For Month End</strong></td>
</tr>
<tr>
<td>Global Hemp Group Inc.</td>
<td></td>
<td>October 2023</td>
</tr>
<tr>
<td><strong>Issuer Address</strong></td>
<td></td>
<td><strong>Date of Report</strong></td>
</tr>
<tr>
<td>#106 – 1169 Mt. Seymour Road</td>
<td></td>
<td>YY/MM/DD</td>
</tr>
<tr>
<td><strong>City/Province/Postal Code</strong></td>
<td></td>
<td>2023/11/05</td>
</tr>
<tr>
<td>North Vancouver, BC  V7H 2Y4</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Issuer Fax No.</strong></td>
<td></td>
<td><strong>Issuer Telephone No.</strong></td>
</tr>
<tr>
<td>N/A</td>
<td></td>
<td>778-726-2900</td>
</tr>
<tr>
<td><strong>Contact Name</strong></td>
<td></td>
<td><strong>Contact Position</strong></td>
</tr>
<tr>
<td>Curt Huber</td>
<td></td>
<td>Director</td>
</tr>
<tr>
<td><strong>Contact Telephone No.</strong></td>
<td></td>
<td><strong>Contact Telephone No.</strong></td>
</tr>
<tr>
<td>778-726-2900</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Email Address</strong></td>
<td></td>
<td><strong>Web Site Address</strong></td>
</tr>
<tr>
<td><a href="mailto:info@globalhempgroup.com">info@globalhempgroup.com</a></td>
<td></td>
<td><a href="http://www.globalhempgroup.com">www.globalhempgroup.com</a></td>
</tr>
</tbody>
</table>